Pfizer Makes Strategic Move with Metsera Acquisition to Boost Growth

New York, NY – Pfizer Inc. announced on September 22, 2025, that it will acquire Metsera, a clinical-stage company focusing on obesity and cardiometabolic disease treatments, which could significantly enhance Pfizer’s growth prospects in the GLP-1 obesity market.

Despite facing challenges, including an 18% decrease in stock value over the past year and a 30% decline over five years, Pfizer is actively expanding its portfolio through strategic acquisitions.

The acquisition could cost Pfizer up to $7.3 billion, depending on the success of Metsera’s drug candidates. The lead candidate, MET-097i, is currently in phase 2 trials and has shown promise by helping participants lose 7.5% of their body weight within 36 days. In addition to MET-097i, Metsera is developing several oral drugs for obesity treatment.

Analysts predict the anti-obesity drug market could reach $120 billion by 2035, making it a lucrative target for Pfizer. The deal with Metsera is expected to close by the end of this year and offers Pfizer new assets that may revitalize its standing in the competitive market.

Previously, Pfizer abandoned a GLP-1 pill due to side effect concerns. However, the company’s move to acquire Metsera reflects its commitment to expanding its pipeline with innovative treatments. As of August 5, Pfizer had 108 drug candidates, but lacked options in the promising GLP-1 obesity sector.

This acquisition is part of Pfizer’s broader strategy to strengthen its research and development efforts and deepen its market presence. The firm reported $12.4 billion in revenue over the trailing 12 months, sufficient to cover annual dividends while pursuing such strategic acquisitions.

Investors remain cautious as Pfizer’s stock struggles, facing skepticism about its growth potential. Still, the company preserves a diversified portfolio and future growth opportunities. Analysts urge potential investors to consider the long-term prospects, as even a single successful drug can significantly improve Pfizer’s situation.

Pfizer’s stock currently trades at a historically low price-to-earnings ratio of less than 13, suggesting potential for significant future gains, making it a buy-and-hold opportunity for patient investors.